Carbetocin Evidence Guide
Carbetocin (Duratocin) is approved in Canada, Europe, and other markets for postpartum hemorrhage prevention following cesarean delivery, with Phase 3 data from the WHO CHAMPION trial confirming non-inferiority to oxytocin. It is not FDA-approved in the US. Its longer duration of action (4-7 hours vs. minutes for oxytocin) is its clinical differentiator. A legitimate approved drug in its specific obstetric niche.
Our Take
Carbetocin (Duratocin) is approved in Canada, Europe, and other markets for postpartum hemorrhage prevention following cesarean delivery, with Phase 3 data from the WHO CHAMPION trial confirming non-inferiority to oxytocin. It is not FDA-approved in the US. Its longer duration of action (4-7 hours vs. minutes for oxytocin) is its clinical differentiator. A legitimate approved drug in its specific obstetric niche.
- Evidence context
- Postpartum hemorrhage prevention (cesarean delivery), long-acting oxytocin receptor agonist research
- Evidence grade
- Level B
- Confidence
- Moderate
- Reference context
- Reported research reference: 100mcg IV single dose immediately after delivery
Benefits and Evidence
- Postpartum Hemorrhage Prevention: Level A, includes human evidence - The WHO CHAMPION trial (nearly 30,000 women) demonstrated that heat-stable carbetocin was non-inferior to oxytocin for PPH prevention. Multiple RCTs confirm efficacy after both cesarean and vaginal delivery.
- Reduced Need for Additional Uterotonics: Level B, includes human evidence - Single-dose carbetocin reduces the need for supplementary uterotonic agents compared to oxytocin infusion, simplifying postpartum management.
- Uterine Tone Maintenance: Level B, includes human evidence - Duration of uterotonic effect (60-120 minutes) exceeds that of a single oxytocin dose (15-30 minutes), providing more sustained uterine tone.
Side Effects and Warnings
- Abdominal pain
- Nausea
- Flushing
- Headache
- Tremor
- Hypotension
- Pruritus
- Metallic taste
Research Dosage References
- <strong>Intravenous</strong> - 100 mcg - Single dose after delivery - Administered as slow IV bolus over 1 minute immediately after delivery of the baby (cesarean) or placenta (vaginal). No repeat dosing required.
- <strong>Intramuscular</strong> - 100 mcg - Single dose after delivery - IM route used in settings where IV access is limited. Heat-stable formulation does not require refrigeration.
Mechanism of Action
Carbetocin acts as a long-acting oxytocin receptor agonist: 1. Oxytocin receptor binding: Binds to the oxytocin receptor (OXTR) on myometrial smooth muscle cells with affinity comparable to oxytocin. 2. Sustained uterine contraction: Induces prolonged rhythmic uterine contractions through calcium mobilization via phospholipase C/IP3 signaling. Single dose provides uterotonic effect lasting 60-120 minutes. 3. Enzymatic resistance: Modified structure resists degradation by aminopeptidases and disulfidases that rapidly inactivate native oxytocin. 4. Hemostatic compression: Sustained uterine contraction compresses blood vessels at the placental site, preventing excessive postpartum blood loss.
Legal Status
Approved in more than 30 countries, including Canada and European markets, for postpartum-hemorrhage prevention. It is not FDA-approved in the United States. Heat-stable carbetocin is included on the WHO Model List of Essential Medicines.
Primary Sources
- Heat-stable carbetocin versus oxytocin to prevent hemorrhage after vaginal birth (CHAMPION trial). New England Journal of Medicine, 2018.
- Carbetocin versus oxytocin for prevention of postpartum hemorrhage at cesarean section. BJOG, 2010.
- Carbetocin for preventing postpartum hemorrhage: a systematic review. Obstetrical & Gynecological Survey, 2012.
Quick Answers
Where is the strongest evidence for Carbetocin?
Carbetocin (Duratocin) is approved in Canada, Europe, and other markets for postpartum hemorrhage prevention following cesarean delivery, with Phase 3 data from the WHO CHAMPION trial confirming non-inferiority to oxytocin. It is not FDA-approved in the US. Its longer duration of action (4-7 hours vs. minutes for oxytocin) is its clinical differentiator. A legitimate approved drug in its specific obstetric niche. Evidence context: Postpartum hemorrhage prevention (cesarean delivery), long-acting oxytocin receptor agonist research.
What are the main side effects of Carbetocin?
Carbetocin side effects and warning signals include Abdominal pain, Nausea, Flushing, Headache, and Tremor.
What evidence level is Carbetocin?
Carbetocin is rated Level B; the listed research status is Approved Outside US.